FKBPL has been implicated in processes associated with cancer, including regulation of tumor growth and angiogenesis with high levels of FKBPL prognosticating for improved patient survival. Understanding how FKBPL levels are controlled within the cell is therefore critical. We have identified a novel role for RBCK1 as an FKBPL-interacting protein, which regulates FKBPL stability at the post-translational level via ubiquitination. Both RBCK1 and FKBPL are upregulated by 17-b-estradiol and interact within heat shock protein 90 chaperone complexes, together with estrogen receptor-a (ERa). Furthermore, FKBPL and RBCK1 associate with ERa at the promoter of the estrogen responsive gene, pS2, and regulate pS2 levels. MCF-7 clones stably overexpressing RBCK1 were shown to have reduced proliferation and increased levels of FKBPL and p21. Furthermore, these clones were resistant to tamoxifen therapy, suggesting that RBCK1 could be a predictive marker of response to endocrine therapy. RBCK1 knockdown using targeted small interfering RNA resulted in increased proliferation and increased sensitivity to tamoxifen treatment. Moreover, in support of our in vitro data, analysis of mRNA microarray data sets demonstrated that high levels of FKBPL and RBCK1 correlated with increased patient survival, whereas high RBCK1 predicted for a poor response to tamoxifen. Our findings support a role for RBCK1 in the regulation of FKBPL with important implications for estrogen receptor signaling, cell proliferation and response to endocrine therapy.
INTRODUCTION
The FKBPL gene encodes a protein with a molecular mass of B39 kDa, with two characteristic regions, the tetratricopeptide repeat domain and a partial peptidyl-prolyl-cis-trans-isomerase domain. These domains are features of the FKBP/immunophilin family of which FKBPL represents a divergent member. The tetratricopeptide repeat domain is required for protein-protein interactions 1 and facilitates interaction with the cellular chaperone, heat shock protein (Hsp)90. 2 Through its interaction with Hsp90, FKBPL has been shown to regulate the stability of the cyclin-dependent kinase inhibitor, p21 3, 4 and also form co-chaperone complexes with the glucocorticoid receptor, androgen receptor and estrogen receptor-a (ERa). [5] [6] [7] FKBPL directly regulates protein levels of ERa and its phosphorylation at Ser118, sensitizing ER-positive breast cancer cell lines to estrogen deprivation and endocrine therapy. 6 Overexpression of FKBPL inhibited the growth of several tumor cell lines, 6, 8 and high FKBPL was also found to correlate with both increased overall survival and distant metastasis-free survival in microarray data sets. 6 This was further supported in a breast cancer tissue microarray where high FKBPL was associated with increased survival and reduced tumor size and grade, 9 highlighting its prognostic value. FKBPL's prognostic potential may also be related to its anti-angiogenic activity; secreted FKBPL and a therapeutic peptide derivative inhibit angiogenesis in vitro and in vivo, resulting in inhibition of human tumor xenograft growth. 10 Together, these data support a role for FKBPL as a tumor suppressor and, therefore, understanding how this protein is regulated is critical. RBCK1 (HOIL-1) encodes a 510 amino-acid protein with several distinct functional domains: a RING-IBR domain, B-Box, two coiledcoil regions and a ubiquitin-like sequence. 11 The RING-IBR consists of two RING fingers and an in-between RING-finger motif making it homologous with E3 ubiquitin ligase enzymes. Functional analysis has identified RBCK1 as an E3 ligase involved in the ubiquitination of PKC, IRP2, SOCS6, BACH1, TAB2/3 and IRF3 proteins. [12] [13] [14] [15] [16] RBCK1 is also involved in the 600-kDa heteromeric linear ubiquitin chain assembly complex 17, 18 responsible for the linear polyubiquitination of NF-kappa-B essential modulator (NEMO) resulting in activation of the nuclear factor-kB pathway involved in immune and inflammatory responses. 19, 20 RBCK1 has been implicated in modulating cell growth through regulation of p53 activation of p21 transcription. 21 RBCK1 contains DNA-binding domains and directly influences the transactivation of numerous genes including, p21, HBv-X and Eya1. [21] [22] [23] It also positively regulates ERa transcription by enhancing promoter binding, resulting in transactivation of ER responsive genes, c-myc, Cyclin D and pS2. 24, 25 Here, we show that RBCK1 is a post-transcriptional regulator of FKBPL, stabilizing FKBPL through ubiquitination. We further show that RBCK1 acts as a co-chaperone within Hsp90/FKBPL/ERa complexes, regulating a number of processes, including ERa transactivation in association with FKBPL, response to endocrine therapy and cell proliferation.
RESULTS

RBCK1 is a novel FKBPL-interacting protein involved in FKBPL ubiquitination
An yeast-2-hybrid screen was used to isolate FKBPL-interacting proteins, identified by their ability to induce expression of three independent reporter genes enabling yeast cell growth on aminoacid drop out media, inducing b-gal activity and inhibiting yeast growth on media containing 5-fluoroorotic acid (Figure 1a) . Three independent clones of RBCK1 were identified as strong interacting partners; these clones spanned the Ubl and RING domains of RBCK1. The mammalian two-hybrid assay was used to confirm and map the interacting domains. Co-transfection of full-length FKBPL and RBCK1 resulted in a 20-fold induction in firefly luminescence over the self-activation control, indicating a strong interaction (Figure 1b) . Deletion of the tetratricopeptide repeat domain in FKBPLD200, FKBPLD151 or FKBPLD86 constructs (Supplementary Figure 1a ) abrogated the interaction with RBCK1. The interaction was confirmed using pull-down assays; full-length but not truncated FKBPLD200 interacted with myc-tagged RBCK1 (Figure 1c) . Mutational analysis of RBCK1 demonstrated an interaction between FKBPL and the myc-tagged RBCK1/DRING mutant, but not the RBCK1/DUbl mutant, confirming that the Ubl was important for its interaction with FKBPL, although the RING domain may still be needed to enhance this interaction (Figure 1d and Supplementary Figure 1b ). To test whether RBCK1 could alter the ubiquitin status of FKBPL, we assessed the ability of full-length RBCK1 and mutated RBCK1 (lacking either the Ubl or RING domain) to ubiquitinate FKBPL. Immunoprecipitation of FKBPL resulted in a characteristic ubiquitin smear when co-transfected with either full-length or RBCK1DRING mutant; no smear was observed when transfected with the RBCK1DUbl mutant (Figure 1e ). This suggests that the Ubl domain of RBCK1 is required for the ubiquitination of FKBPL. To assess the type of ubiquitin chain that RBCK1 attaches to FKBPL, two ubiquitin mutants were utilized, one with all lysine residues mutated to arginine, except K48, and the other with only K48 mutated to arginine (Supplementary Figure 1c) ; wild-type ubiquitin was used as a control. FKBPL was ubiquitinated in the presence of both mutants and wild-type ubiquitin (Figure 1f) , suggesting that the ubiquitin chains attached to FKBPL are not linked via any of the seven classical lysine residues. RBCK1 has been shown to work in tandem with RNF3 to form linear ubiquitin chains that are formed by N to C terminal conjugation rather than from lysine residues. 14, 16, 17, 19 RBCK1 could therefore modify FKBPL via this type of ubiquitination.
RBCK1 regulates FKBPL protein levels
To assess the functional potential of the interaction between RBCK1 and FKBPL, RBCK1 was transiently overexpressed in MCF-7 cells at both the mRNA and protein levels (Figure 2a ). This coincided with a significant increase in FKBPL protein (Po0.05), whereas FKBPL mRNA levels remained constant (Figure 2a and Supplementary Figure 2a) . MCF-7 clones stably overexpressing RBCK1, 3.1 Â 8 and 3.1 Â 10, had increased levels of RBCK1 at the mRNA and protein levels ( Figure 2b and Supplementary  Figure 2b ). In support of the transient transfections, FKBPL protein levels were significantly elevated in both RBCK1 clones compared with the empty vector control, 3.1E21 (Po0.05; Figure 2b and Supplementary Figure 2b) , whereas mRNA levels remained unchanged. When a RBCK1-targeted small interfering RNA (siRNA) approach was used, RBCK1 knockdown resulted in a significant decrease in FKBPL protein (Po0.05) and no significant change at the mRNA level (Figure 2c and Supplementary Figure 2c) , suggesting that RBCK1 is involved in post-translational stabilization of FKBPL. Supplementary Figure 2d shows RBCK1 knockdown following transfection of individual siRNAs rather than the pool.
RBCK1 modulates p21 and ER expression with subsequent effects on cell proliferation Previous studies have implicated both FKBPL and RBCK1 involvement in p21 transcription and protein stability. 3, 4, 21 To further characterize the significance of this interaction, we assessed the levels of p21 in the MCF-7 clones stably expressing RBCK1. Quantitative reverse transcriptase-PCR analysis revealed a 1.5-fold increase in p21 mRNA in the 3.1 Â 10 cell line (Po0.01) and a 5.5-fold increase in 3.1 Â 8 cell line (Po0.01; Figure 3a and Supplementary Figure 3a) . Western blot analysis demonstrated an approximately twofold increase in p21 protein levels in 3.1 Â 10 (Po0.05) and 3.1 Â 8 (Po0.001) cell lines compared with the 3.1E21 empty vector control (Figure 3a) . ERa mRNA and protein levels were not significantly altered in RBCK1-overexpressing cell lines (Figure 3b and Supplementary Figure 3b) ; however, RBCK1 knockdown in MCF7 and T47D cell lines resulted in decreased ERa ( Figure 3c and Supplementary Figure 3c ). In addition, we investigated the proliferative/clonogenic capacity of RBCK1 stable clones and following RBCK1 knockdown. Clonogenic survival was significantly inhibited in the 3.1 Â 10 and 3.1 Â 8 clones by 50% (P ¼ 0.007) and 99% (P ¼ 6.6 Â 10 À 13 ), respectively, compared with MCF-7 parental and 3.1E21 cells (Figure 3d ), whereas RBCK1 siRNA-transfected parental MCF-7 cells showed a threefold increase in clonogenic survival compared with non-targeting siRNA controls (P ¼ 0.025, Figure 3e ). RBCK1 depletion also resulted in a significant increase in cell proliferation ( Figure 3f ).
RBCK1 is an estrogen-inducible gene that associates with the FKBPL molecular complex
We have previously demonstrated that FKBPL has a role in ER signaling and is regulated by 17-b-estradiol (E2) 6 and have determined that RBCK1 is also involved in this pathway. To investigate the role of ER in RBCK1 regulation, MCF-7 cells were treated with 10 À 8 mol/l E2 for a 48 h time course. RBCK1 levels increased 4 h after treatment with E2 and further increased at later time points (Figure 4a ). The increase in RBCK1 expression was reversed following 24 h treatment with the antiestrogen, tamoxifen ( Figure 4b) ; this was more dramatic in the MCF-7 cells compared with the T47D cells. To assess whether RBCK1 was present in the previously reported Hsp90/ER/FKBPL molecular complex, 6 co-immunoprecipitations were performed þ / À E2 in MCF-7 and T47D cells. In MCF-7 cells, endogenous RBCK1 did not co-precipitate in the absence of E2 but coprecipitated with FKBPL and ERa in the presence of E2 (Figure 4c ). In T47D cells, RBCK1 co-precipitated with HSP90 only in the absence of E2, and co-precipitated with FKBPL, Hsp90 and ER in the presence of E2 (Figure 4c ). These data imply that E2 is required for the formation of a robust complex comprising FKBPL/RBCK1/ HSP90/ERa and that the composition of the complex is cell-line dependent. 
RBCK1 is a potential ER coactivator
Previous studies have shown that RBCK1 is a co-activator of HBv X-protein-induced transactivation 22 and affects ER signaling; 24, 25 therefore, its effect on ER transactivation was assessed in light of evidence that RBCK1 was present in the ER/FKBPL/HSP90 complex. Using parental and FKBPL stably overexpressing (3.1D2) MCF-7 cells, FKBPL overexpression increased ER-mediated transactivation over parental control in the presence of E2 only (Po0.05). However, transfection of the 3.1D2 cell line with RBCK1 caused a 4.5-fold increase in transcriptional activation in the absence of ligand (P ¼ 0.05), which was not further increased following the addition of E2 (Po0.01; Figure 5a ). These data suggest that RBCK1 can regulate ER transactivity in an FKBPL concentration-dependent manner. As RBCK1 seems to enhance ER transactivation and may represent an ER transcriptional coactivator, the ability of ER to bind the LxxLL consensus-binding motif of ER coactivator proteins in the presence of increased RBCK1 levels was assessed (Figure 5b ). 3.1D2 cells demonstrated a significant increase in the ability of ER to bind this motif (P ¼ 0.0127) compared with parental cells. However, increased RBCK1 levels resulted in decreased ability of ER to bind the coactivator motif in both parental and FKBPL stable cells, suggesting that RBCK1, in its role as an ER co-activator, is recruited to the LxxLLbinding region of ER, blocking the ability of ER to bind this motif.
As we identified that the interaction between FKBPL and RBCK1 was increased in the presence of E2, we hypothesized that both FKBPL and RBCK1 could be involved in regulation of ER-responsive genes. Using chromatin immunoprecipitation, we assessed whether FKBPL and RBCK1 were recruited to the promoter of the ER-responsive gene, pS2. Following treatment with 10 nM E2, FKBPL, RBCK1 and ERa were bound to the promoter region of the pS2 ( Figure 5c ); RNA polymerase II was also recruited and acted as a positive control. Analysis of the pS2 distal region confirmed that this interaction was specific to the promoter sequence of pS2 ( Figure 5c ). We then assessed the effect of RBCK1 on pS2 protein expression and found that pS2 levels were significantly increased in the RBCK1-overexpressing clone, 3.1 Â 8 compared with the empty vector control, 3.1E21 (Po0.05; Figure 5d ). Following treatment with 1 mM tamoxifen, pS2 expression was inhibited by 50% in the 3.1E21 control clone and 42% in the 3.1 Â 8 clone. However, pS2 levels in the tamoxifentreated 3.1 Â 8 clone were similar to the non-treated 3.1E21 control (Figure 5e ), suggesting an attenuation of tamoxifen antagonist activity in the presence of high RBCK1 levels. The data support a role for FKBPL and RBCK1 in regulating this ER responsive gene.
High RBCK1 levels promote agonistic effects of tamoxifen High levels of ER co-activator proteins have been associated with conferring a tamoxifen-resistant phenotype; therefore, we RBCK1 modulates FKBPL and affects tumor growth C Donley et al investigated the effects of RBCK1 expression on tamoxifen sensitivity. As pS2 levels remain high in the 3.1 Â 8 clone following tamoxifen treatment and FKBPL has been shown to affect tamoxifen sensitivity in vitro, 6 we assessed whether RBCK1 could also affect sensitivity to tamoxifen. Following treatment with 1-10 mM tamoxifen, clonogenic survival in the 3.1 Â 8 clone demonstrated resistance to tamoxifen compared with MCF-7 parental and 3.1E21 controls (Po0.001; Figure 6a ). Moreover, in this clone, tamoxifen had an agonistic effect, increasing clonogenicity at all doses except the highest dose. Following RBCK1 siRNA knockdown, increased tamoxifen sensitivity was detected in cell lines, MCF7 (1-10 mM tamoxifen, Figures 6b) and T47D (1 mM tamoxifen, Figure 6c ) compared with non-targeted siRNA controls. This strongly supports a correlation between RBCK1 levels and tamoxifen sensitivity.
High RBCK1 expression correlates with improved patient survival but poor response to tamoxifen To assess the clinical relevance of our in vitro findings, several microarray patient data sets (Supplementary Table 1), GSE7390,   26   GSE2034 27 and GSE22219, 28 were analyzed for RBCK1 expression and correlated with patient survival using the Kaplan-Meier analysis. The GSE2034 data set showed a significant correlation (Po0.05, Mantel-Cox log-rank test) between high RBCK1 levels and increased overall patient survival (Figure 7a ). The GSE7390 data set showed a trend in which high RBCK1 levels correlated with increased overall and distant metastasis-free survival, whereas there was a significant correlation with relapse-free survival (Po0.05, Mantel-Cox log-rank test; Supplementary Figure 4) . The GSE22219 data set showed a trend toward significance, where high levels of RBCK1 correlated with increase distant metastasisfree survival (Supplementary Figure 5) . As both FKBPL and RBCK1 were shown to correlate with increased patient survival separately, we assessed the effect of the two proteins together on patient survival by using the ratio of the two markers. The GSE22219 data set was further separated for low FKBPL/low RBCK1 (Low), low FKBPL/high RBCK1, high FKBPL/low RBCK1 and high FKBPL/high RBCK1 (High), and distant relapse-free survival assessed. High levels of both FKBPL and RBCK1 significantly correlated (Po0.05, Mantel-Cox log-rank test) with increased distant relapse-free survival (Figure 7b ). These data suggest that high levels of FKBPL and RBCK1 are advantageous for patient survival and predict for a less aggressive tumor phenotype, supporting our in vitro growth inhibitory findings.
We assessed how FKBPL and RBCK1 levels had an impact on patient response to tamoxifen. FKBPL and RBCK1 seems to work in tandem to regulate cell growth; however, our in vitro data suggested that RBCK1 may work in an opposing manner to FKBPL with respect to tamoxifen efficacy. This was evaluated further by analysis of the GSE12093 data set. 29 In support of our in vitro studies and previous data, 6 following treatment with tamoxifen, high FKBPL/low RBCK1 (FKBPL:RBCK142.478) significantly correlated with increased distant metastasis-free survival in patients, whereas patients with low FKBPL/high RBCK1 (FKBPL:RBCK1 p2.478) exhibited poor distant metastasis-free survival (Po0.05; Figure 7c ). 
DISCUSSION
FKBPL has demonstrated an increasingly important role in tumorigenesis by a variety of signaling pathways including
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The level of FKBPL expression in breast cancer cells is important, with high levels correlating with tumor growth inhibition and increased sensitivity to endocrine therapy. 6 However, very little is known of how FKBPL is regulated or which other proteins are involved in its signaling. Here we provide evidence that RBCK1 is an FKBPL-interacting partner that stabilizes FKBPL expression, affects ER signaling and response to endocrine therapy.
RBCK1 interacts only with full-length FKBPL and the Ubl domain of RBCK1 is required for this interaction. This domain is crucial for the E3 ligase activity of RBCK1 and has a role in substrate recognition, 12 suggesting that FKBPL may be a RBCK1 substrate. RBCK1 acts in tandem with another ubiquitin ligase RNF31/HOIP to form a 600 kDa linear ubiquitin chain assembly complex, which generates multiple and different ubiquitin chains, including linear ubiquitination chains. 17 Although the functional significance is poorly characterized, linear ubiquitination by RBCK1 has been shown to increase the stability of the TNF-R1 signalling complex (TNF-RSC) complex. 18 Our studies indicate that RBCK1 does not ubiquitinate FKBPL through classical lysine residues, and may therefore stabilize FKBPL via linear ubiquitination; this would need to be further validated to support this hypothesis.
FKBPL protein stabilization by RBCK1 resulted in increased levels of the cyclin-dependent kinase inhibitor, p21, causing a decrease in clonogenic survival and proliferation. Previously, RBCK1 and FKBPL have both been implicated in controlling p21 levels at the transcriptional and protein levels, respectively. 3, 4, 6, 21 Our data are the first to report that FKBPL and RBCK1 may work together to regulate p21 and cell cycle progression. Using the clinical data set GSE22219, analysis of RBCK1 and FKBPL levels revealed that patients with high levels of both FKBPL and RBCK1 demonstrated increased survival, whereas patients with low FKBPL/high RBCK1 or high RBCK1/low FKBPL had poor survival outcomes. This supports our in vitro data where high RBCK1 increases FKBPL and RBCK1 modulates FKBPL and affects tumor growth C Donley et al p21 levels and inhibits tumor growth. FKBPL has previously been identified as a prognostic marker 6,9 and we propose that RBCK1 also represents a novel prognostic marker in breast cancer.
We have shown that RBCK1 has an important role in the FKBPL/ ER signaling pathway. RBCK1 is a member of the Hsp90/FKBPL molecular complex that binds ERa in the presence of E2. In addition, RBCK1 levels are rapidly upregulated by E2 and this was reversed by tamoxifen; RBCK1 is necessary for ER-mediated transcription in response to E2 24 and is critical to ER-mediated transcription, and therefore would need to be rapidly induced by . High RBCK1 expression correlates with increased patient survival but poor tamoxifen response. Kaplan-Meier curves of breast cancer patients for (a), relapse-free survival (GSE2034) stratified with RBCK1 expression (b), distant relapse-free survival (GSE 22219) stratified using the ratio of FKBPL and RBCK1 expression (c), distant metastasis-free survival from patients treated with tamoxifen therapy (GSE 12093) and stratified with RBCK1:FKBPL expression.
RBCK1 modulates FKBPL and affects tumor growth C Donley et al E2 to facilitate regulation of this pathway. We provide evidence that RBCK1 in conjunction with FKBPL and ERa bind to the promoter of the ER-responsive gene, pS2, and regulate ER transactivation. RBCK1 has previously been shown to act as a transcriptional coregulator and low RBCK1 levels have been associated with decreased transcription of the ER-regulated genes c-myc, cyclin D1 and pS2, [21] [22] [23] [24] [25] and this effect was attributed to RBCK1's regulation of ERa levels. We have also shown that RBCK1 depletion results in a concomitant decrease in ERa expression, although high RBCK1 levels did not significantly affect ERa expression. We therefore suggest that RBCK1 is an ER coactivator as high RBCK1 levels caused increased pS2 expression; increased ER transactivity even in the absence of E2; and reduced ER capacity to bind its coactivator consensus sequence, LxxLL, suggesting that RBCK1 occupies this binding site on ER in its role as an ER co-activator. There is evidence that steroid receptor/ immunophilin complexes exist in the nucleus 30, 31 and are involved in chromatin regulation and association with DNA. 32 Immunophilins have been shown to act as scaffold proteins to facilitate interactions between transcription factors and transcriptional co-activators, 32 and therefore FKBPL may represent an immunophilin important in facilitating RBCK1-mediated transcriptional activation. We have demonstrated that RBCK1 overexpression increases p21 expression, suggesting that RBCK1-mediated stabilization of FKBPL has subsequent downstream effects on p21 stability. 4, 6 RBCK1 overexpression resulted in resistance to tamoxifen and appeared to promote the agonistic effects of tamoxifen by increasing cell growth; RBCK1 knockdown using targeted siRNA reversed these effects. In addition, pS2 levels remained high following tamoxifen treatment in the RBCK1-overexpressing cell line, 3.1 Â 8, suggesting that the antagonist activity of tamoxifen was compromised. Elevated levels of the ER co-activator, AIB1, have been shown to increase ER signaling resulting in tamoxifen resistance, 33 and as a potential ER co-activator RBCK1 seems to act in a similar way. Elevated co-activator levels prevent the recruitment of the NCoR1 and NCoR2 repressor proteins and the inhibition of activation function-2 of ER, 34 therefore reversing the therapeutic effect of tamoxifen. To assess the clinical relevance of these findings, we examined the GSE12093 data set from patients treated with adjuvant tamoxifen therapy; 29 the ratio of FKBPL-RBCK1 was assessed. In support of our in vitro data and previous work, 6 high levels of FKBPL and low levels of RBCK1 significantly correlated with increased distant metastasis-free survival in patients treated with tamoxifen.
In summary, we provide evidence that, in addition to its role as an ER coactivator, RBCK1 is an important regulator of FKBPL and p21 with downstream consequences for tumor growth and response to tamoxifen. RBCK1 may therefore act as a novel prognostic and predictive biomarker in breast cancer.
MATERIALS AND METHODS
Cell culture and transfections
The MCF-7, T47D and COS-7 cell lines were obtained from ATCC (Teddington, Middlesex, UK). The L132 cell line was obtained from Gibco (Paisley, Scotland, UK), UK. Cell lines were maintained as monolayers in medium supplemented with 10% fetal calf serum (Dulbecco's modified Eagle's medium: Invitrogen, Paisley, UK for MCF-7, T47D and COS-7 cells; and minimum essential medium: Invitrogen for L132 cells). Cell lines were authenticated by short tandem repeat profiling carried out by the suppliers. Testing revealed that cells were mycoplasma free. All experiments were carried out between passages 1 and 20. The MCF-7 FKBPL-overexpressing cell line, 3.1D2, was generated as previously described. 6 Transient and stable transfections were carried out using empty vector pcDNA3.1 (as a control) or pcDNA3.1/RBCK1 and Lipofectamine Plus according to the manufacturer's instructions, except when stated otherwise. Stably transfected MCF-7 cells were selected using 750 mg/ml G418 (Sigma, Gillingham, UK). For RBCK1 knockdown analysis, 50 nM of a pool of RBCK1 siRNA or Non Targeting control (Stealth RNAi, Invitrogen) were transfected using Oligofectamine reagent (Invitrogen), according to the manufacturer's instructions. Cells were assayed 72 h after transfection.
Yeast two-hybrid assay
The ProQuest Yeast Two-Hybrid System (Life Technologies, Paisley, UK) was used to identify FKBPL-interacting proteins. Briefly, in-frame cloning of full-length FKBPL into the pDBLeu-GAL4 DNA-binding domain plasmid was carried out and used to screen a human fetal brain cDNA library (Invitrogen) constructed in the pPC86-GAL4 activation domain plasmid. Plasmids were transformed into MaV203 yeast cells using the polyethylene glycol/lithium acetate method according to the manufacturer's instructions and transformants were plated onto selective medium to determine the induction of three independent reporter genes. DNA sequencing and BLAST sequence analysis (http://www.ncbi.nlm.nih.gov) was performed to identify interacting cDNA.
Mammalian two-hybrid assay
The CheckMate Mammalian-Two Hybrid (Promega, Southhampton, UK) was used to confirm protein interactions in a mammalian cell system. FKBPL and RBCK1 mutants were engineered using the QuikChange Site-Directed Mutagenesis (Stratagene, Leicester, UK) method according to the manufacturer's instructions. L132 cells at 60-80% confluence were transfected with pBIND/FKBPL (full-length or mutant) or pACT/RBCK1 (full-length or mutant) and pG5luc plasmid. After 24 h, cells were analyzed using the Dual-Glo Luciferase assay (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity and presented as relative light units.
Clonogenic assay/growth assays Cells were plated in Dulbecco's modified Eagle's medium þ 10% fetal calf serum and incubated for 16 days at 37 1C. Alternatively, after 24 h, medium was replaced with Dulbecco's modified Eagle's medium þ 10% fetal calf serum containing 1 mM tamoxifen (Sigma) and incubated under normal conditions for 16 days and stained with 0.4% crystal violet. Using the XCelligence system (Roche, Welwyn Garden City, UK) to assess growth, 1 Â 10 4 MCF-7 cells were seeded into an E-16 multi-well plate (Roche) in triplicate and cell growth was measured every 15 min for 96 h.
Co-immunoprecipitation
To confirm protein interactions, L132 cells were transfected with HA-FKBPL or HA-FKBPLD200 and Myc-RBCK1. Myc-RBCK1DUbl and Myc-RBCK1DRING mutants were engineered using the QuikChange Site-Directed Mutagenesis (Stratagene) method according to the manufacturer's instructions. COS-7 cells were transfected with FKBPL and Myc-RBCK1DUbl or Myc-RBCK1DRING. All plasmids were transfected using Lipofectamine 2000, according to the manufacturer's instructions. Following incubation, cells were lysed (lysis buffer; 1% Igepal, 0.1% SDS, 0.05% sodium deoxycholate, 1 protease inhibitor tablet and 1 PhosSTOP tablet (Roche)), precleared and lysates were incubated with antibody-bound Protein G-Sepharose beads (Cancer Research, London, UK) overnight at 4 1 C. Beads were washed in lysis buffer and resuspended in 5 Â reducing sample buffer (Pierce, Cramlington, UK).
Ubiquitination assay
The ubiquitin constructs, pEFIRES-HA-ubiquitin, pEFIRES-HA-K48R and pEFIRES-HA-R48K, were a gift from Professor Yossi Yarden, as previously described. 35 To assess protein ubiquitination, T47D cells were co-transfected with HA-Ubiquitin, Myc-RBCK1 and either Myc-RBCK1DUbl/Myc-RBCK1DRING mutants or HA-Ubiquitin^K48R/HA-Ubiquitin^R48K mutants. Transfections were carried out using Lipofectamine 2000 according to the manufacturer's instructions. Samples were immunoprecipitated using FKBPL antibody and resuspended in non-reducing sample buffer (Pierce).
Western blot analysis
Samples were subjected to SDS-polyacrylamide gel electrophoresis using the XCellSureLock Mini-Cell system (Invitrogen) and transferred onto nitrocellulose membranes (Millipore, Watford, UK) and probed accordingly. Antibody binding was detected using Supersignal West Pico Chemiluminescent substrate (Pierce) according to the manufacturer's instructions.
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Real-time reverse transcriptase PCR RNA was isolated from cells using STAT60 and transcribed using Transcriptor First Strand cDNA Synthesis kit (Roche) as per the manufacturer's instructions. Real-time PCR was performed using the Lightcycler 480 PCR machine (Roche) to quantify the expression levels of FKBPL, RBCK1, p21 using a validated Taqman mono-hydrolysis PCR primer probes (Roche). Glyceraldehyde 3-phosphate dehydrogenase was used as an internal control to normalize mRNA expression.
ER element transactivation assay MCF-7 parental and 3.1D2 FKBPL stable cells were transfected with pcDNA3.1/RBCK1, pGL2-ERE luciferase reporter plasmid and the pBINDRenilla plasmid to normalize for transfection efficiency. After 24 h, cells were treated with dimethyl sulfoxide vehicle control or 10 À 8 M E2 for 24 h, and were then analyzed using the Dual-Glo Luciferase Assay System (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity and presented as relative light units.
ERa coactivator motif-binding assay
The NE-PER nuclear and cytoplasmic extraction kit (Pierce) was used in accordance with the manufacturer's instructions to isolate the nuclear extracts from parental and 3.1D2 FKBPL stable cells transfected with RBCK1 for use in the nuclear receptor peptide ERa-binding assay (Active Motif, La Hulpe, Belgium). Briefly, 40 mg of each nuclear extract was added to peptide-coated wells and incubated for 1 h. The wells were washed in ice-cold 1 Â wash buffer, ERa primary antibody was diluted to 1:500 and added to each well. Samples were incubated for 1 h and washed as previously described. Secondary antibody was diluted to 1:1000, added to each well and incubated for 1 h. After washing, developer solution was added to each well. Stop solution was added and a colorimetrical change was detected using the Tecan plate reader at 450 nm.
Chromatin immunoprecipitation assay MCF-7 cells were grown to 70% confluency, and then medium was replaced with phenol red-free Dulbecco's modified Eagle's medium and 10% charcoal-stripped fetal calf serum for 48 h. Cells were treated with 10 nM estradiol or vehicle control for 1 h. Cellular chromatin was crosslinked using 1.5% formaldehyde in phosphate-buffered saline at room temperature for 15 min. Chromatin immunoprecipitation was performed following the protocol by Hosey et al. 36 ; antibodies included IgG and RNA polymerase II (Active Motif), ER-a (HC-20 clone, Santa Cruz), AIB1 (Abcam), FKBPL (ProteinTech) and RBCK1 (Abcam) . Primers for PCR analysis amplified the pS2 promoter regions, forward primer sequence: 5 0 -TTCCGGCCATCTCTCACTAT-3 0 and reverse primer sequence: 5 0 -CGGG GATCCTCTGAGACA-3 0 .
Gene expression analysis
Gene expression analysis was performed on publicly available microarray data sets from the National Centre for Biotechnology Information Gene Expression Omnibus. [26] [27] [28] [29] Analysis was performed using Partek Genomics Suite (Partek, Inc., St Louis, MO, USA) and Bioconductor (Fred Hutchinson Cancer Research Center, Seattle, WA, USA). Raw microarray data were imported to Partek GS and analyzed using robust multichip average to generate normalized expression values. Expression values for FKBPL (probe: 219187_at) and RBCK1 (probe: 207713_s_at (GSE2034, GSE7390, GSE12093), 2810717 (GSE22219)) were assessed for normal distribution using Kolmogorov-Smirnov test and were used to stratify samples with low or high FKBPL or RBCK1 expression. To identify an optimal cut-off of expression values to stratify the samples, maxstat package in Bioconductor was used. The Kaplan-Meier survival curves were generated based on the stratified data and associated survival data, and were compared using Mantel-Cox log-rank test.
Quantification and statistical analysis
Image acquisition and densitometric analysis was performed using UVP VisionWorksLS (Ultra-Violet Products Ltd, Cambridge, UK) and ImageJ software (National Institutes of Health, Bethesda, MD, USA). One-way analysis of variance was used for all statistical analyses, unless otherwise indicated.
